[Comment] Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer

Imaging has a crucial role in the diagnosis and staging of prostate cancer. Prostate-specific membrane antigen (PSMA)-PET is the newest imaging method available and, in addition to greatly improving imaging, PSMA-targeted ligands can be used for therapy. Several antibodies and small molecules have been developed as PET therapeutic agents, and these agents are rapidly becoming routine in clinical practice globally.1